Researchers reported a number of important findings in ovarian cancer treatment at the 2019 Annual Meeting of the American Society of Clinical Oncology:

Substituting PARP inhibitors for chemotherapy studied in treatment of relapsed ovarian cancer

A number of clinical trials evaluated the substitution of PARP inhibitors for chemotherapy in the treatment of relapsed ovarian cancer, including:

  • SOLO3. In this phase III trial, women with BRCA-mutated, platinum-sensitive relapsed ovarian cancer gained significant clinical benefit from treatment with the PARP inhibitor olaparib, as compared with chemotherapy.

  • AVANOVA. The results of this phase II trial showed that the combination of the PARP inhibitor niraparib plus the targeted therapy bevacizumab significantly improved progression-free survival in women with platinum-sensitive relapsed ovarian cancer.

  • CLIO. This phase II trial showed favorable results of olaparib therapy versus standard-of-care chemotherapy in the treatment of platinum-resistant relapsed ovarian cancer.

What Patients Need to Know

PARP is a type of enzyme that helps repair DNA. In cancer treatment, PARP inhibitors are used to prevent cancer cells from repairing their damaged DNA. This can cause the cancer cells to die, especially those with defective DNA repair pathways, such as BRCA1/2-associated ovarian cancers.

Combination of chemotherapies better in treatment of ovarian cancer in elderly women

According to the results of the EWOC-1 trial, elderly women with stage III/IV epithelial ovarian cancer had better survival outcomes when treated with the combination of carboplatin and paclitaxel, compared to single-agent carboplatin.

What Patients Need to Know

The primary endpoint of the study was the ability of the women to complete six chemotherapy courses without disease progression, discontinuation of treatment or death.